Wedbush reiterated an Outperform rating and a 12-month price target of $7 for Aprea Therapeutics (APRE). The note is supportive but unchanged; Aprea remains a clinical-stage biotech with lead candidate APR-1051 in a Phase 1 trial.
Wedbush reiterated an Outperform rating and a 12-month price target of $7 for Aprea Therapeutics (APRE). The note is supportive but unchanged; Aprea remains a clinical-stage biotech with lead candidate APR-1051 in a Phase 1 trial.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
